Brief: Monopar Therapeutics Reports Second Quarter 2022 Financial Results

Monopar Therapeutics

11/08/2022 15:03

Aug 11 (Reuters) - Monopar Therapeutics Inc  MNPR.O :
    * MONOPAR THERAPEUTICS REPORTS SECOND QUARTER 2022 FINANCIAL
RESULTS AND RECENT PROGRAM DEVELOPMENTS
    * MONOPAR THERAPEUTICS INC - NET LOSS FOR Q2 OF 2022 WAS
$2.8
MILLION OR $0.22 PER SHARE
    * MONOPAR THERAPEUTICS INC - CASH AND CASH EQUIVALENTS AS OF
JUNE
30, 2022 WERE $16.5 MILLION
    * MONOPAR THERAPEUTICS INC - ANTICIPATES THAT ITS CURRENT
CASH AND
CASH EQUIVALENTS WILL FUND: COMPLETION OF PHASE 2B PORTION OF
VOICE CLINICAL TRIAL
    * MONOPAR THERAPEUTICS INC -  ANTICIPATES THAT ITS CURRENT
CASH
AND CASH EQUIVALENTS WILL FUND COMMENCEMENT OF PHASE 3 PORTION
OF VOICE CLINICAL TRIAL
    * MONOPAR THERAPEUTICS -  ANTICIPATES CURRENT CASH AND CASH
EQUIVALENTS WILL FUND PHASE 1B CAMSIRUBICIN CLINICAL TRIAL
THROUGH AT LEAST SEPTEMBER 2023

Source text for Eikon:  ID:nGNX4v8Cfh 
Further company coverage:  MNPR.O 

 ((reuters.briefs@thomsonreuters.com;))